Sign up to save your podcasts
Or
Share Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By The Wall Street Journal & Gimlet
4.2
53575,357 ratings
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Journal.
View all
WSJ Tech News Briefing
1,630 Listeners
WSJ What’s News
4,305 Listeners
WSJ Your Money Briefing
1,743 Listeners
Bloomberg Businessweek
422 Listeners
WSJ Opinion: Potomac Watch
2,794 Listeners
The Daily
110,928 Listeners
WSJ Minute Briefing
657 Listeners
Up First from NPR
55,879 Listeners
Bold Names
1,452 Listeners
Today, Explained
10,071 Listeners
Post Reports
5,386 Listeners
The Ezra Klein Show
15,302 Listeners
The Big Take
156 Listeners
Bad Bets
1,319 Listeners
WSJ Opinion: Free Expression
576 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
133 Listeners
The Headlines
447 Listeners